Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | ECE1 | P42892 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5405234 | 1.00 | HCRTR2 (0.33) | HCRTR2AGTR2CTSLCTSBCTSK | |
| SCHEMBL5416646 | 0.90 | AGTR2 (0.35) | HCRTR2AGTR2CTSLCTSBCTSK | |
| SCHEMBL5412639 | 0.89 | MMP1 (0.32) | HCRTR2AGTR2CTSLCTSBCTSK | |
| SCHEMBL5406472 | 0.89 | ALDH1A1 (0.34) | AGTR2CTSLCTSBCTSKLOX | |
| SCHEMBL5410585 | 0.87 | PTGIR (0.33) | HCRTR2KIF11MMP2MMP9 | |
| SCHEMBL5410582 | 0.87 | PTGIR (0.33) | HCRTR2KIF11MMP2MMP9 | |
| SCHEMBL5409337 | 0.84 | HCRTR2 (0.34) | HCRTR2KIF11 | |
| SCHEMBL5412637 | 0.83 | RAB9A (0.40) | — | |
| SCHEMBL5412632 | 0.83 | RAB9A (0.40) | — | |
| SCHEMBL5405194 | 0.83 | TLR2 (0.35) | HCRTR2MMP2MMP9HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020040146-A1 | Pyrrolidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040146-A1 | Pyrrolidine derivatives | PREP, PEPD, MMP3 | HCRTR2 2575/4885AGTR2 493/4885CTSL 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.